Table 4.
CCD for formulation and optimization of ‘ZnO NP–Ams’ nanoantibiotic.
| Runs | X1 Coded Uncoded |
X1 Coded Uncoded |
X1 Coded Uncoded |
ZOI (mm) Experimental Predicted Residual |
|||||
|---|---|---|---|---|---|---|---|---|---|
| 1. | +1 | 80 | +1 | 65 | +1 | 36 | 26 | 24.56 | 1.44 |
| 2. | +1 | 80 | −1 | 25 | −1 | 12 | 25 | 23.06 | 1.94 |
| 3. | −1 | 30 | +1 | 65 | −1 | 12 | 22 | 21.81 | 0.19 |
| 4. | +1 | 80 | +1 | 65 | −1 | 12 | 27 | 26.81 | 0.19 |
| 5. | +1 | 80 | −1 | 25 | +1 | 36 | 25 | 23.81 | 1.19 |
| 6. | −1 | 30 | +1 | 65 | +1 | 36 | 20 | 20.56 | 0.56 |
| 7. | −1 | 30 | −1 | 25 | +1 | 36 | 25 | 23.81 | 1.19 |
| 8. | −1 | 30 | −1 | 25 | −1 | 12 | 22 | 22.06 | 0.06 |
| 9. | −2 | 5 | 0 | 45 | 0 | 24 | 21 | 20.68 | 0.32 |
| 10. | 0 | 55 | −2 | 5 | 0 | 24 | 21 | 22.43 | 1.43 |
| 11. | 0 | 55 | 0 | 45 | −2 | 0 | 21 | 21.43 | 0.43 |
| 12. | +2 | 105 | 0 | 45 | 0 | 24 | 24 | 25.68 | 1.68 |
| 13. | 0 | 55 | +2 | 85 | 0 | 24 | 23 | 22.93 | 0.07 |
| 14. | 0 | 55 | 0 | 45 | +2 | 48 | 20 | 20.93 | 0.93 |
| 15. | 0 | 55 | 0 | 45 | 0 | 24 | 26 | 26.22 | 0.22 |
| 16. | 0 | 55 | 0 | 45 | 0 | 24 | 26 | 26.22 | 0.22 |
| 17. | 0 | 55 | 0 | 45 | 0 | 24 | 26 | 26.22 | 0.22 |
| 18. | 0 | 55 | 0 | 45 | 0 | 24 | 26 | 26.22 | 0.22 |
| 19. | 0 | 55 | 0 | 45 | 0 | 24 | 26 | 26.22 | 0.22 |
| 20. | 0 | 55 | 0 | 45 | 0 | 24 | 26 | 26.22 | 0.22 |
Note: X1 = Concentration of ZnO Nanoparticles; X2 = Concentration of Ampicillin/Sulbactam (Ams) antibiotic; X3 = Conjugation time; ZOI: Zone of inhibition in mm; Concentration units of ZnO NP and Ams were in µg/mL, and conjugation time was in hour.